Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.
This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
The conversation centers on the crucial role of nurses and support staff in educating patients and ensuring optimal outcomes with adalimumab biosimilars. Nurses are highlighted as key educators who interact closely with patients, providing training on device usage and addressing any issues that arise. Support staff, including specialty pharmacists and biologics coordinators, also play essential roles in managing patient concerns, such as delays in medication delivery or copay assistance.
Providers emphasize the importance of patient education from the outset, including information on risks, side effects, and access to copay assistance programs. Proactive patient engagement is encouraged, with patients urged to communicate any issues promptly to facilitate timely resolution.
Collaboration between healthcare providers, pharmaceutical companies, and support staff is crucial in navigating the complexities of insurance coverage and product availability. Open communication and ongoing education ensure that patients receive comprehensive support throughout their treatment journey, despite potential changes in coverage and policies over time.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Not So Different: Dr Gary Lyman Explains How to Ensure Physician Confidence in Biosimilars
August 15th 2021Gary Lyman, MD, MPH, an oncologist and hematologist, discusses some of the issues holding physicians back from prescribing biosimilars and some ways to ensure provider confidence in biosimilars.
Phase 3 Study of Amgen Biosimilar to Eculizumab Meets Primary End Points
August 24th 2022Eculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis.
Denosumab Biosimilar Demonstrates Noninferiority to Prolia in Postmenopausal Osteoporosis
July 30th 2022Results from a phase 3 trial suggested similar efficacy and safety of the denosumab biosimilar candidate Arylia (AryoGen Pharmed) to the reference product (Prolia) in postmenopausal osteoporosis.
Biosimilars Check-In: Celltrion Pushes for Yuflyma in Europe; Xbrane Updates on Ranibizumab Filing
July 21st 2022In recent weeks, Celltrion Healthcare furthered its adalimumab biosimilar (Yuflyma) by launching the drug in Spain and Portugal and starting a clinical trial in France while Xbrane Biopharma provided an update on the FDA filing of its ranibizumab biosimilar.